Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei Xing

Showing results (531-540 of 533) with videos related to

Pageof 54
Sort By:
You have reached the last page of results.This site can display upto 533 results.
Cancers|March 28, 2025
Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small-Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases?Sarah E Glynn, Claire M Lanier, Ariel R Choi, et al.
Journal of Ethnopharmacology|April 8, 2026
Erchen Decoction Promotes Inguinal White Adipose Tissue Browning via the M2 Macrophage-Sympathetic Axis to Ameliorate Obesity in MiceJia-Wei Chen, Mao-Hui Liu, Zhi-Da Yang, et al.
Nature Communications|July 2, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trialNan Niu, Jinqi Xue, Guanglei Chen, et al.
Pageof 54

Showing results (531-540 of 533) with videos related to

Sort By:
Pageof 54
You have reached the last page of results.This site can display upto 533 results.
Cancers|March 28, 2025
Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small-Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases?Sarah E Glynn, Claire M Lanier, Ariel R Choi, et al.
Journal of Ethnopharmacology|April 8, 2026
Erchen Decoction Promotes Inguinal White Adipose Tissue Browning via the M2 Macrophage-Sympathetic Axis to Ameliorate Obesity in MiceJia-Wei Chen, Mao-Hui Liu, Zhi-Da Yang, et al.
Nature Communications|July 2, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trialNan Niu, Jinqi Xue, Guanglei Chen, et al.
Pageof 54